Pulmonary pleomorphic carcinoma with pseudoprogression during nivolumab therapy and the usefulness of tumor markers : A case report

Pseudoprogression was reported as one of the unconventional responses during immune checkpoint inhibitor therapy. A 70-year-old man with pulmonary pleomorphic carcinoma received nivolumab therapy. Pleural effusion and pulmonary metastasis increased, however then shrank and serum cytokeratin 19 fragment levels decreased. Serum tumor marker might help to distinguish pseudoprogression.

Media Type:

Electronic Article

Year of Publication:

2018

Contained In:

Clinical case reports - Vol. 6, No. 7 (2018), p. 1338-1341

Language:

English

Contributors:

Yoshimura, Akihiro
Takumi, Chieko
Tsuji, Taisuke
Hamashima, Ryosuke
Shiotsu, Shinsuke
Yuba, Tatsuya
Urata, Yoji
Hiraoka, Noriya

Links:

Volltext

Keywords:

Case Reports
Immune checkpoint inhibitor
Nivolumab
Pseudoprogression
Pulmonary pleomorphic carcinoma
Tumor marker

Notes:

Date Revised 28.09.2020

published: Electronic-eCollection

Citation Status PubMed-not-MEDLINE

Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Physical Description:

Online-Ressource

doi:

10.1002/ccr3.1627

PMID:

29988633

PPN (Catalogue-ID):

NLM286675102